Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
46.69%
median of 509 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Cullinan Therapeutics, Inc.
Market Cap
$1.06B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.06B
Gross Margin
73.53%
TTM Avg
70.13%
3Y Avg
70.04%
5Y Avg
68.74%
Market Cap
$1.05B
Gross Margin
11.80%
TTM Avg
10.80%
3Y Avg
10.72%
5Y Avg
10.72%
Market Cap
$1.05B
Gross Margin
53.74%
TTM Avg
53.23%
3Y Avg
56.54%
5Y Avg
58.23%
Market Cap
$1.02B
Gross Margin
79.71%
TTM Avg
80.13%
3Y Avg
81.57%
5Y Avg
-49.18%
Market Cap
$1.01B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.12B
Gross Margin
75.86%
TTM Avg
76.84%
3Y Avg
76.91%
5Y Avg
76.44%
Market Cap
$1.12B
Gross Margin
77.26%
TTM Avg
80.62%
3Y Avg
79.35%
5Y Avg
80.86%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | $1.06B | 0.00% | 0.00% | 0.00% | 0.00% |
| Teladoc Health, Inc. (TDOC)vs › | $1.06B | 73.53% | 70.13% | 70.04% | 68.74% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.05B | 11.80% | 10.80% | 10.72% | 10.72% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.05B | 53.74% | 53.23% | 56.54% | 58.23% |
| Immatics N.V. (IMTX)vs › | $1.04B | 100.00% | 100.00% | 100.00% | 64.23% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.02B | 79.71% | 80.13% | 81.57% | -49.18% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $1.01B | 0.00% | 0.00% | 0.00% | 0.00% |
| IRadimed Corporation (IRMD)vs › | $1.12B | 75.86% | 76.84% | 76.91% | 76.44% |
| Castle Biosciences, Inc. (CSTL)vs › | $1.12B | 77.26% | 80.62% | 79.35% | 80.86% |
| Aktis Oncology, Inc. (AKTS)vs › | $995.46M | 100.00% | 100.00% | 50.00% | 50.00% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
